Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

This observational study will compare outcomes of a prospectively-enrolled cohort of Hematopoietic Stem Cell Transplant (HCT) recipients with outcomes of a cohort of age-matched historical non-HCT controls. Patients undergoing alloHCT will receive HCT in a US transplant center and be reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) using well-established CIBMTR report forms and data collection procedures as well as a study-specific supplemental form. Data on the historical non-HCT controls will be collected at 14 US academic centers. These centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.

NCT Number	NCT02934477
Lead Sponsor	Center for International Blood and Marrow Transplant Research Collaborators: National Marrow Donor Program, National Institutes of Health (NIH), National Cancer Institute (NCI)
Conditions	Myelofibrosis
Enrollment	650 participants
Start Date	2016-11
Primary Completion	2026-11 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2023-08-30